Shanghai, China, July 28, 2026 – Asieris Pharmaceuticals and the Obstetrics & Gynecology Hospital of Fudan University (also known as Shanghai Red House Women’s Hospital) today officially signed a comprehensive framework cooperation agreement. Leveraging their respective core strengths in innovative drug R&D and clinical medicine, the two parties will engage in all‑round industry‑university‑research collaboration in the fields of female cervical lesions and HPV‑related diseases. Together, they will explore novel treatment models, advance clinical and translational medicine research, and cultivate professional talent, with the goal of ensuring that scientific and technological innovation truly benefits women’s health.
This collaboration aims to build a synergistic pathway that connects clinical needs, practice, and technological innovation. Asieris has accumulated innovative products and technological expertise in female cervical lesions and HPV related diseases; its non invasive photodynamic therapy offers a new fertility preserving option for patients with cervical precancerous lesions. The Red House Hospital, a top tier Grade 3A specialized hospital with over 140 years of history, possesses strong capabilities in obstetrics & gynecology, with deep clinical and research foundations in cervical diseases, gynecological oncology, and reproductive medicine. Under the agreement, the two parties will jointly establish a National Fertility Friendly Cervical Care Center, collaborate on clinical research, translational medicine, and product development, and strengthen talent cultivation. The outcomes are expected to establish standardized diagnosis and treatment systems and provide important evidence based references for cervical lesion management.
Jiang Hua, President of the Obstetrics & Gynecology Hospital of Fudan University, stated that promoting high‑level industry‑university‑research collaboration between medical institutions and innovative enterprises is a key pathway to advancing medical innovation and improving disease prevention and treatment capabilities. This partnership represents a deep integration of clinical needs and technological innovation. The two parties will focus on cervical lesions and HPV‑related diseases to explore and build a full‑chain collaboration model encompassing “clinical needs – scientific research – results translation – treatment optimization – patient services,” jointly creating a benchmark for synergistic development between hospitals and enterprises.
Dr. Kevin Pan, Founder, Chairman, and CEO of Asieris Pharmaceuticals, commented that the Red House Hospital’s century‑long commitment to safeguarding women’s health aligns closely with Asieris’ founding mission of innovating for women’s health. This cooperation is a significant exploration of combining innovative technology with clinical needs and carries positive social implications. Through this partnership, we hope to provide standardized, high‑quality treatment options for patients with cervical lesions, especially young women with fertility aspirations, and accelerate the translation of research findings into clinical practice. Looking ahead, the company will continue to deepen collaborations with top‑tier medical institutions, build an industry‑university‑research collaborative ecosystem, and jointly explore new pathways for precision health management.
The signing of this strategic agreement marks an important step forward in collaborative innovation between domestic innovative pharmaceutical companies and high‑level obstetrics & gynecology specialized hospitals in the field of cervical health. Both parties expressed their commitment to fully leverage their respective strengths in scientific innovation and clinical practice to jointly advance the diagnosis and treatment of cervical lesions and HPV‑related diseases, contributing actively to the “Healthy China” strategy and the building of a fertility‑friendly society.